Haemonetics (NYSE: HAE) reported Q4 EPS of $1.29, $0.02 better than the analyst estimate of $1.27. Revenue for the quarter came in at $346 million versus the consensus estimate of $337.04 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.